Welcome to our dedicated page for MBX Biosciences SEC filings (Ticker: MBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MBX Biosciences, Inc. (Nasdaq: MBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company and emerging growth company, MBX uses filings such as Forms S-1, 10-K, 10-Q, and 8-K to describe its Precision Endocrine Peptide™ (PEP™) platform, clinical programs, risk factors, and capital-raising activities.
In its S-1 registration statement, MBX outlines its focus on novel precision peptide therapies for endocrine and metabolic disorders and details key product candidates, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, imapextide (MBX 1416) for post-bariatric hypoglycemia, and MBX 4291 for obesity. Subsequent 8-K filings report material events such as topline results from the Phase 2 Avail™ trial of canvuparatide, initiation of the Phase 1 trial of MBX 4291, public equity offerings, and changes in board and committee roles.
Through this page, users can review MBX’s periodic financial reports, which discuss research and development spending, cash and marketable securities, and expectations about funding operations, as well as prospectus materials that describe intended uses of offering proceeds. Form 8-K filings also summarize key clinical data, trial designs, and future development plans for the company’s programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical results, financing terms, and governance updates. Real-time updates from EDGAR, along with structured access to material event reports and registration statements, make this page a central resource for analyzing MBX’s regulatory and financial disclosures.
MBX Biosciences, Inc. is asking stockholders to vote at a fully virtual 2026 annual meeting on June 4, 2026, held via live webcast. Stockholders of record as of April 10, 2026, when 47,570,485 common shares were outstanding, may vote online, by phone, mail, or during the meeting.
Stockholders will elect two Class II directors, Patrick J. Heron and Edward T. Mathers, to serve until 2029, and vote on ratifying Ernst & Young LLP as independent registered public accounting firm for 2026. MBX paid Ernst & Young $491,678 in audit fees for 2025 and $944,548 for 2024.
The company has a classified board split into three classes and four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Science and Medicine. As an emerging growth company and smaller reporting company, it uses scaled executive-pay disclosure. In 2025, CEO P. Kent Hawryluk received salary of $625,000, an annual cash bonus of $359,375, and option awards valued at $1,998,092, for total compensation of $2,990,867.
MBX Biosciences director Steven L. Hoerter received a stock option grant as part of his non-employee director compensation. The options have an exercise price of $27.08 per share and expire on November 21, 2035. The grant vests in equal monthly installments over one year from November 6, 2025, and was adjusted so his 2025 equity compensation does not exceed $1,000,000 in aggregate grant date fair value under the company’s director compensation policy.
MBX Biosciences, Inc. reported that director Steven L. Hoerter received a grant of stock options covering 33,751 shares of common stock. The options have an exercise price of $24.74 per share and were awarded as part of the company’s Non-Employee Director Compensation Policy.
The footnotes state that these grants were adjusted so the director’s total 2025 equity compensation does not exceed $1,000,000 based on grant date fair value under FASB Topic ASC 718. The grant vests in equal monthly installments over one year, contingent on his continued service to the company.
MBX files a Section 144 notice to sell 1,061 shares of Common Stock related to Restricted Stock Vesting that occurred on 03/23/2026.
The filing also reports a prior disposition by Richard Bartram of 10,000 shares on 03/16/2026 for $300,471. The filing names Fidelity Brokerage Services LLC as the broker and lists an account reference for the proposed sale.
MBX Biosciences, Inc. reported that Chief Financial Officer John W. Smither filed an initial Form 3 as an officer of the company. The filing lists him as Chief Financial Officer and does not report any purchases, sales, gifts, or other transactions in MBX Biosciences securities.
MBX proposed the sale of 10,000 shares of Common Stock via a Form 144 notice. The filing shows 7,500 shares from an option granted 04/20/2022 and 2,500 shares from an option granted 11/07/2022, with transactions routed through Fidelity Brokerage Services LLC on 03/16/2026. The filing lists an aggregate value of $300,470.62.
MBX Biosciences, Inc. President & CEO P. Kent Hawryluk reported an open-market purchase of 18,500 shares of Common Stock on March 13, 2026, at a weighted average price of $28.4142 per share.
The shares were bought through the P. Kent Hawryluk Revocable Trust, with prices ranging from $28.28 to $28.48 per share. Following this transaction, the trust holds 486,777 shares indirectly, and his direct holdings are reported at 728,274 shares. The filing notes that he disclaims beneficial ownership of the trust shares except for any pecuniary interest.
MBX Biosciences, Inc. filed a Form S-3 shelf registration that includes a sales agreement prospectus supplement to sell up to $250,000,000 of common stock from time to time under an Open Market Sale agreement with Jefferies LLC.
The registration statement establishes a base prospectus permitting the company to offer various securities (common stock, preferred stock, debt, warrants and units) on a continuous or delayed basis under separate prospectus supplements. The sales agreement supplement governs the mechanics of at‑the‑market offerings under the Jefferies arrangement and sales may commence from time to time after the effective date.
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders using its proprietary Precision Endocrine Peptide (PEP™) platform. The company engineers long-acting peptide prodrugs with extended time-action profiles and low peak-to-trough ratios for less frequent dosing and potentially better tolerability.
Lead program canvuparatide (MBX 2109) targets chronic hypoparathyroidism with once-weekly parathyroid hormone replacement and has shown positive Phase 2 results; a Phase 3 trial is planned for the third quarter of 2026. Obesity candidate MBX 4291, a GLP‑1/GIP co-agonist prodrug, is in a Phase 1 trial and is designed for potential once-monthly dosing.
The company is also advancing imapextide (MBX 1416), a long-acting GLP‑1 receptor antagonist for post-bariatric hypoglycemia, now in a Phase 2a trial with topline results expected in the second quarter of 2026. MBX relies on third-party manufacturers, in-licenses key PEP™ intellectual property from Indiana University entities, and faces typical clinical, regulatory, funding and competitive risks highlighted in extensive risk factor disclosures.
MBX Biosciences reported a larger full-year 2025 net loss of $86.97M, up from $61.92M in 2024, as it increased investment in its pipeline. Research and development spending rose to $79.16M, while general and administrative expenses grew to $18.90M as the company expanded its operations.
As of December 31, 2025, MBX held $373.71M in cash, cash equivalents and marketable securities, and subsequently raised an additional $85.4M through its ATM program, for pro forma cash and investments of $459.1M, which it expects will fund operations into 2029. The company is preparing a Phase 3 trial of once-weekly canvuparatide for hypoparathyroidism targeted to start in Q3 2026, advancing MBX 4291 in Phase 1 for obesity with 12-week data anticipated in Q4 2026, and running a Phase 2a trial of imapextide for post-bariatric hypoglycemia with results expected in Q2 2026.